COHANCE Cohance Lifesciences Q3 FY25 results (Oct–Dec 2024) and concall
Management summary
- Suven Pharmaceuticals reported a strong recovery in Q3 FY25, characterized by a 40% surge in pro forma combined revenue and a doubling of its Pharma CDMO business.
- The company is aggressively pivoting towards high-growth niche technologies like ADCs and Oligonucleotides through the acquisitions of NJ Bio and Sapala Organics.
- While 9M FY25 growth remains modest at 5% due to earlier headwinds in specialty chemicals, management is confident in an accelerated growth trajectory for FY26 and beyond.
Source: Inve concall analysis and management guidance record.
What they filed
| Line item | Q3 FY25 |
|---|---|
| Revenue | 676 |
| EBITDA | 237 |
| Net profit | 153 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Revenue
Total Revenue Revenue · by FY30 · High confidence $1 billion
Pro forma Combined Revenue Growth Revenue · FY25 · High confidence Positive YoY Growth
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2Revenue from Phase-3 molecules that cleared clinical trials Partial
At this stage we haven't seen any acceleration in the growth from those two commercial molecules... we expect the demand to come back shortly.
Investors are looking for immediate monetization of the late-stage pipeline; management suggests a lag between trial clearance and commercial volume ramp-up.
Asked by Darshit Shah
NJ Bio Acquisition Accounting and Forward Liability Partial
The forward liability is on account of the liability to acquire the balance equity of both Sapala and NJ Bio... there's around Rs. 550 crore of goodwill which is sitting there.
Clarifies the ₹651 crore liability on the balance sheet as a future obligation to buy out remaining stakes in recent acquisitions.
Asked by Gagan Thareja
Unlock risks & concerns, Q4 FY25 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 3 risks, concerns & management red flags
- Watchlist triggers for Q4 FY25
- +2 more guidance targets & verbatim management quotes
- +1 more analyst Q&A exchange & evasion checks
- Full section-by-section call narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





